AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

AngioDynamics Inc. (ANGO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

11.04

-0.06 (-0.54%)

At close: Feb 07, 2025, 3:59 PM

11.26

1.99%

After-hours Feb 07, 2025, 04:47 PM EST

undefined% (undefined)

Bid	10.46
Market Cap	446.74M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-5.59
PE Ratio (ttm)	-1.97
Forward PE	n/a
Analyst	Buy

Ask	11.26
Volume	307,996
Avg. Volume (20D)	699,890
Open	11.05
Previous Close	11.10
Day's Range	11.00 - 11.16
52-Week Range	5.26 - 13.50
Beta	undefined

About ANGO

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequ...

[Show more]

Industry Medical - Instruments & Supplies

Sector Healthcare

IPO Date Jun 1, 2004

Employees 748

Stock Exchange NASDAQ

Ticker Symbol ANGO

Website https://www.angiodynamics.com

Analyst Forecast

According to 3 analyst ratings, the average rating for ANGO stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 8.70% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

AngioDynamics Inc. is scheduled to release its earnings on Apr 3, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+37.66%

AngioDynamics shares are trading higher after the ... Unlock content with Pro Subscription

2 months ago

+23.29%

AngioDynamics shares are trading higher after the company announced the FDA has granted 510(k) clearance for its Nanoknife system for prostate tissue ablation.

News

1 week ago · zacks.com

ANGO Stock Looks Promising on New Ischemia Study for Auryon System

AngioDynamics initiates the AMBITION BTK RCT and registry to advance treatment for patients with chronic limb-threatening ischemia and below-the-knee peripheral artery disease.

1 week ago · businesswire.com

AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

3 weeks ago · seekingalpha.com

AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares

AngioDynamics' fiscal Q2'25 results exceeded expectations, with Med Tech growing 25% and delivering better gross margins, boosting confidence in achieving high single-digit revenue growth and double-d...

1 month ago · https://thefly.com

AngioDynamics price target raised to $15 from $12 at Canaccord

Canaccord raised the firm's price target on AngioDynamics to $15 from $12 and keeps a Buy rating on the shares. AngioDynamics reported one of its strongest quarters in recent memory, the analyst tells...

1 month ago · zacks.com

AngioDynamics Stock Up on Q2 Earnings Beat, Gross Margin Declines

ANGO registers overall strong top-line results on a pro-forma basis in second-quarter fiscal 2025, driven by strength in the Med Tech business.

1 month ago · seekingalpha.com

AngioDynamics: A Surgical Approach To Market Growth

AngioDynamics, Inc.'s Q2 2025 earnings beat expectations, with non-GAAP EPS at -$0.04 and revenue at $73.02 million, driving a 35% stock surge. Med Tech division shines, with 25% revenue growth and ke...

1 month ago · seekingalpha.com

AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript

AngioDynamics, Inc. (NASDAQ:ANGO ) Q2 2025 Earnings Conference Call January 8, 2025 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Stephen Trowbridge - Executive V...

1 month ago · zacks.com

AngioDynamics (ANGO) Reports Q2 Loss, Tops Revenue Estimates

AngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.05 per share a year ago.

1 month ago · businesswire.com

AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results

1 month ago · businesswire.com

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

Load More News